Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
Rhea-AI Summary
Relmada Therapeutics (Nasdaq: RLMD) will report first quarter 2026 financial results and host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET. The company will discuss results for the quarter ended March 31, 2026 and provide updates on recent business and clinical progress.
Participant dial-in numbers and a webcast link are provided; a replay will be available in the Investors section of the Relmada website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – RLMD
On the day this news was published, RLMD gained 6.94%, reflecting a notable positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $54M to the company's valuation, bringing the market cap to $837.02M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RLMD slipped 0.81% while the only peer in the momentum scanner, CAMP, was down 12.81% with no news, suggesting today’s action reflects stock-specific positioning rather than a coordinated biotech move.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Earnings date notice | Neutral | -2.7% | Announcement of Q4 2025 results date and related conference call details. |
| Nov 07 | Earnings date notice | Neutral | +1.5% | Scheduling of Q3 2025 results release and investor conference call. |
Prior earnings date notices for RLMD led to modest moves of -2.69% and +1.53%, with no clear directional bias.
Over recent months, Relmada has used earnings date press releases to signal upcoming financial and business updates via conference calls and webcasts. Prior earnings date announcements on Nov 07, 2025 and Mar 12, 2026 preceded moves of +1.53% and -2.69%, respectively, indicating historically small reactions to this type of scheduling news. Today’s notice continues that pattern by setting expectations for when first quarter 2026 results and recent progress will be discussed.
Historical Comparison
Past earnings date notices moved RLMD by an average of -0.58%, with individual reactions of -2.69% and +1.53%. Today’s -0.81% move fits this modest pattern.
This continues RLMD’s pattern of announcing timing for quarterly results via conference call, following similar earnings date notices for Q3 2025 and Q4 2025.
Regulatory & Risk Context
An effective S-3 filed on 2026-04-03 registers 33,685,096 shares for resale from a private placement. The company will not receive proceeds from these resales, though it previously raised approximately $160.0 million when the securities were issued. A 424B3 on 2026-04-09 reflects active usage of this registration.
Market Pulse Summary
The stock moved +6.9% in the session following this news. A strong positive reaction aligns with RLMD’s elevated technical setup, trading above its 200-day MA at 7.35. Historically, earnings date notices have produced modest moves of -2.69% and +1.53%, so a large gain would mark a departure from past behavior. Investors have an effective S-3 resale registration in the background, which could influence liquidity dynamics around future catalysts.
Key Terms
central nervous system medical
AI-generated analysis. Not financial advice.
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2026, and recent business progress.
Conference Call and Webcast Information:
- Date: Tuesday, May 12, 2026 at 4:30 PM ET
- Participant Dial-in (US): 1-800-717-1738
- Participant Dial-in (International): 1-646-307-1865
- Webcast Access: Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
